BioCentury
ARTICLE | Financial News

Thrasos raises $21M in series D

April 1, 2015 1:34 AM UTC

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $21 million in a series D round led by new investor BDC Capital and existing investor SR One. Current investors Advanced Technology Ventures; Fonds de solidarite FTQ; Lumira Capital; MP Healthcare Venture Management; Pappas Ventures; and SW Co also participated.

In 3Q15 Thrasos plans to complete an ongoing Phase II study of THR-184 to prevent acute kidney injury (AKI) in patients undergoing cardiac surgery. The company expects data in 1H16. The small peptide that selectively activates activin receptor-like kinase 2 ( ALK2; ACVR1) and ALK3 has Fast Track designation in the U.S. to prevent cardiac surgery-associated AKI. ...